Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Certara Launches Simcyp Access to Expand Simulator Availability

PRINCETON, NJ – Mar. 9, 2017 – Certara today announced the launch of Simcyp Access, a new cloud-based licensing approach that provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects.

Solution: PBPK Modeling & Simulation
More Info

Certara Launches First Global Quantitative Systems Pharmacology Consortium

PRINCETON, NJ – Jan. 25, 2017 – Certara today announced that it is launching a Quantitative Systems Pharmacology (QSP) Immunogenicity Consortium. Modeled after Certara’s highly successful Simcyp Consortium, the QSP Immunogenicity Consortium brings together leading biopharmaceutical companies in a pre-competitive environment to cooperatively develop an Immunogenicity Simulator.

More Info

Certara Launches Version 16 of Its Simcyp Population-based Simulator

PRINCETON, NJ – Jan. 10, 2017 – Certara today announced that it has released version 16 of its Simcyp Population-based Simulator. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for determining first-in-human dose selection, designing more efficient and effective clinical studies, evaluating new drug formulations, and predicting drug-drug interactions (DDIs) and pharmacokinetic (PK) outcomes in clinical populations.

More Info
Learn More